Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO).

Abivax SA (Euronext Paris & Nasdaq: ABVX) ('Abivax' or the 'Company'), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis (UC), will be presented during the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) on February 21-24, 2024, in Stockholm, Sweden.

'We are delighted that all four submitted abstracts have been accepted for presentations at ECCO. We look forward to scientific exchange with the IBD community at ECCO,' said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax. 'The ECCO Congress provides an excellent platform to present new data and to continue raising awareness of the unique mechanism of action of obefazimod, which available data indicate exerts its anti-inflammatory activity by stabilizing the immune response in patients with ulcerative colitis.'

Abivax has also sponsored a scientific symposium titled 'Expanding the Armamentarium: Emerging MOAs for Treating Ulcerative Colitis' featuring speakers Prof. Bruce E. Sands, M.D., M.S. (United States), and Prof. Raja Atreya, M.D. (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.

The Symposium will be broadcasted live and is accessible publicly here. No ECCO registration is required to view the broadcast.

For more information visit the Abivax booth at the ECCO exhibitor hall (booth #15) or see congress details at the ECCO website.

Obefazimod data to be presented:

Presentation Title

Session

Presenter

Presentation/ Session Number

Session Hall

Date and Time (CET)

Digital Oral Presentations

Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial

Session 2: Clinical trials 1

Prof. Severine Vermeire, M.D., Ph.D.

Head of the IBD Center at the University Hospitals Leuven, Belgium, and principal investigator in Europe for the study programs conducted and ongoing with obefazimod in UC

EC24-1273

Digital Oral Presentation (DOP)-12

A7

Feb. 22, 2024

Presentation time: 5:57-6:03 p.m.

Session time: 5:45-6:45 p.m.

Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose

DOP Session 8: Clinical trials 3

Prof. Bruce E. Sands, M.D., M.S.

Dr. Burrill B. Crohn Professor of Medicine and Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY

EC24-1275

Digital Oral Presentation (DOP)-71

A12

Feb. 23, 2024

Presentation time: 6:22-6:28 p.m.

Session time: 5:40-6:40 p.m.

Poster Presentations

Obefazimod and its active metabolites ABX-464-N-Glu act by stabilizing protein-protein interaction among key RNA biogenesis partners, CBC and ARS2

Guided Poster Session

Didier Scherrer, Ph.D.

Chief Scientific Officer, Abivax

EC24-1272

Poster Presentation-025

Poster Exhibition Hall A

Feb. 23, 2024

Session time: 12:40-1:40 p.m.

Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis

Guided Poster Session

Prof. Parambir S. Dulai, M.D.

Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Northwestern University, Evanston, Illinois.

EC24-1277

Poster Presentaition-985

Poster Exhibition Hall A

Feb. 23, 2024

Session time: 12:40-1:40 p.m.

About Obefazimod

Obefazimod, Abivax's lead investigational drug candidate, is an oral small molecule that was demonstrated to enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC have generated positive topline data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical trial in Crohn's disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.

Contacts:

Abivax Communications

Regina Jehle

regina.jehle@abivax.com

+33 06 24 60 69 63

Abivax Investor Relations

Patrick Malloy

patrick.malloy@abivax.com

+1 847 987 4878